Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Bilaterally positive biopsy cores are associated with non-organ-confined disease in prostate cancer patients eligible for active surveillance.

Umbehr MH, Largo RA, Gfeller S, Tremp M, Poyet C, Paul M, Sulser T, Müntener M.

Urol Int. 2014;93(2):176-81. doi: 10.1159/000357121. Epub 2014 Mar 15.

PMID:
24643133
2.

Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.

Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS.

Eur Urol. 2012 Sep;62(3):462-8. doi: 10.1016/j.eururo.2012.03.011. Epub 2012 Mar 17.

PMID:
22445138
3.

Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.

Gallina A, Maccagnano C, Suardi N, Capitanio U, Abdollah F, Raber M, Salonia A, Scattoni V, Rigatti P, Montorsi F, Briganti A.

BJU Int. 2012 Jul;110(2 Pt 2):E64-8. doi: 10.1111/j.1464-410X.2011.10762.x. Epub 2011 Nov 17.

4.
5.

Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.

Iremashvili V, Manoharan M, Rosenberg DL, Soloway MS.

BJU Int. 2013 Apr;111(4):574-9. doi: 10.1111/j.1464-410X.2012.11127.x. Epub 2012 May 4.

6.

Ability of sextant biopsies to predict radical prostatectomy stage.

Wills ML, Sauvageot J, Partin AW, Gurganus R, Epstein JI.

Urology. 1998 May;51(5):759-64.

PMID:
9610589
7.

Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.

Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC Jr; SEARCH Database Study Group.

J Urol. 2003 Jun;169(6):2136-41.

PMID:
12771735
8.

A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.

Graefen M, Haese A, Pichlmeier U, Hammerer PG, Noldus J, Butz K, Erbersdobler A, Henke RP, Michl U, Fernandez S, Huland H.

J Urol. 2001 Mar;165(3):857-63.

PMID:
11176486
9.

[Correlation of the anatomo-pathological staging of radical prostatectomy specimens with the amount of cancer in the preoperative sextant biopsy].

Ojea Calvo A, Núñez López A, Domínguez Freire F, Alonso Rodrigo A, Rodríguez Iglesias B, Benavente Delgado J, Barros Rodríguez JM, Gómez-González MC, González Piñeiro A, Otero García M, Nogueira March JL.

Actas Urol Esp. 2003 Jun;27(6):428-37. Spanish.

PMID:
12918149
10.

Percent of cancer in the biopsy set predicts pathological findings after prostatectomy.

Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Chang SS, Cookson MS.

J Urol. 2002 May;167(5):2032-5; discussion 2036.

PMID:
11956432
11.

Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.

Reese AC, Landis P, Han M, Epstein JI, Carter HB.

J Urol. 2013 Dec;190(6):2033-8. doi: 10.1016/j.juro.2013.05.015. Epub 2013 May 13.

PMID:
23680308
12.

The number of cores taken in patients diagnosed with a single microfocus at initial biopsy is a major predictor of insignificant prostate cancer.

Villa L, Capitanio U, Briganti A, Abdollah F, Suardi N, Salonia A, Gallina A, Freschi M, Russo A, Castiglione F, Bianchi M, Rigatti P, Montorsi F, Scattoni V.

J Urol. 2013 Mar;189(3):854-9. doi: 10.1016/j.juro.2012.09.100. Epub 2012 Sep 25.

PMID:
23022004
13.

Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance.

Abdollah F, Suardi N, Capitanio U, Gallina A, Sun M, Villa L, Scattoni V, Bianchi M, Tutolo M, Fossati N, Karakiewicz P, Rigatti P, Montorsi F, Briganti A.

BJU Int. 2013 Aug;112(4):E234-42. doi: 10.1111/bju.12152. Epub 2013 Jun 7.

15.

Factors predicting prostatic biopsy Gleason sum under grading.

Stackhouse DA, Sun L, Schroeck FR, Jayachandran J, Caire AA, Acholo CO, Robertson CN, Albala DM, Polascik TJ, Donatucci CF, Maloney KE, Moul JW.

J Urol. 2009 Jul;182(1):118-22; discussion 123-4. doi: 10.1016/j.juro.2009.02.127. Epub 2009 May 17.

PMID:
19447436
16.

Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings.

Karram S, Trock BJ, Netto GJ, Epstein JI.

Am J Surg Pathol. 2011 Sep;35(9):1351-5. doi: 10.1097/PAS.0b013e3182217b79.

PMID:
21836493
17.

Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.

Freedland SJ, Presti JC Jr, Terris MK, Kane CJ, Aronson WJ, Dorey F, Amling CL; SEARCH Database Study Group.

J Urol. 2003 Jun;169(6):2129-35.

PMID:
12771734
19.

The number of cores at first biopsy may suggest the need for a confirmatory biopsy in patients eligible for active surveillance-implication for clinical decision making in the real-life setting.

Villa L, Salonia A, Capitanio U, Scattoni V, Abdollah F, Suardi N, Dell'Oglio P, Freschi M, Montorsi F, Briganti A.

Urology. 2014 Sep;84(3):634-41. doi: 10.1016/j.urology.2014.02.070. Epub 2014 Jul 22.

PMID:
25059594
20.

Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance.

Ploussard G, de la Taille A, Terry S, Allory Y, Ouzaïd I, Vacherot F, Abbou CC, Salomon L.

Urol Oncol. 2013 Oct;31(7):1060-6. doi: 10.1016/j.urolonc.2011.12.018. Epub 2012 Jan 31.

PMID:
22300755

Supplemental Content

Support Center